制药生产率差距 - - 尽管有过渡性改善,但研发效率逐渐下降
Kenneth D S Fernald1, Philipp C Förster1, Eric Claassen1
1Vrije Universiteit Amsterdam, Athena Institute, De Boelelaan 1085, 1081 HV Amsterdam, the Netherlands.
Drug discovery today
|September 6, 2024
概括
尽管近期药品研发效率稳定,但仍然是一个挑战. 较高的晚期临床试验失败率表明,药物开发中持续的转变不太可能.
科学领域:
- 制药行业 制药行业 制药行业
- 药物开发 药物开发
- 生物技术是生物技术.
背景情况:
- 新型药物的研发 (R&D) 成本超过35亿美元.
- 五十年来的趋势显示,制药研发效率正在下降.
- 最近的报道表明,研发效率的潜在转变.
研究的目的:
- 执行制药研发效率的系统级分析.
- 为了确定最近的改进是否代表结构性转变或短暂的逆转.
- 分析2012年至2023年之间的趋势.
主要方法:
- 分析了200家最大的制药公司的财务数据.
- 对新药批准的审查.
- 审查了2012年至2023年期间进行的超过8万项临床试验.
主要成果:
- 制药行业最近在研发效率方面表现出稳定.
- 临床试验后期较高的消耗率持续存在.
- 在研发效率方面没有取得持续的转变.
结论:
- 尽管稳定,但在制药研发方面仍然存在重大挑战.
- 高的后期消耗率阻碍了真正的研发效率回归.
- 该行业在实现一致的研发生产率方面面临着持续的障碍.
相关概念视频
Drug Discovery: Overview
7.7K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.7K
Biopharmaceutics and Pharmacokinetics: Overview
1.9K
Understanding drugs, drug products, and their performance in pharmaceutical science is pivotal. Drugs, whether simple molecules or complex compounds, are designed to interact with the body's biological systems to diagnose, treat, or prevent diseases. Drug products include various delivery systems such as tablets, capsules, injections, and inhalers. The performance of these drug products is gauged by their ability to deliver the active ingredient to the desired site of action at the...
1.9K
Bioequivalence: Overview
949
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
949
Nonlinear Pharmacokinetics: Causes of Nonlinearity
151
Nonlinearity in drug pharmacokinetics is caused by various factors influencing how a drug is absorbed, distributed, metabolized, and excreted. Understanding these nonlinear processes is crucial for predicting drug behavior in the body and optimizing drug dosing regimens.
Nonlinear drug absorption can occur when the process is rate-limited by solubility, carrier-mediated transport systems, or saturation of the presystemic gut wall or hepatic metabolism. For instance, high doses of riboflavin...
Nonlinear drug absorption can occur when the process is rate-limited by solubility, carrier-mediated transport systems, or saturation of the presystemic gut wall or hepatic metabolism. For instance, high doses of riboflavin...
151
Chronopharmacokinetics: Time-Dependent Pharmacokinetics
107
Chronopharmacokinetics studies the temporal change in drug absorption and elimination. These changes can be cyclical or non-cyclical. Cyclical changes occur over a regular interval, while non-cyclical changes occur over a longer, irregular period.
Time-dependent pharmacokinetics refers to non-cyclical changes in drug rate processes over a period of time. It can lead to nonlinear pharmacokinetics, where the relationship between drug concentration and time is not proportional. Non-cyclical...
Time-dependent pharmacokinetics refers to non-cyclical changes in drug rate processes over a period of time. It can lead to nonlinear pharmacokinetics, where the relationship between drug concentration and time is not proportional. Non-cyclical...
107
Dose-Response Relationship: Potency and Efficacy
4.3K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
4.3K


